CRL EVP reports vesting of 5,456 performance shares

Charles River Laboratories International EVP Joseph W. LaPlume reported equity transactions in company stock.

Accepted by SEC EDGAR 02/03/2026 - 04:36 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Charles River Laboratories International EVP Joseph W. LaPlume reported equity transactions in company stock. On January 30, 2026, he acquired 5,456 shares of common stock at $0 when performance share units granted on May 26, 2023 vested after meeting performance goals. On the same date, 1,749 shares were withheld and disposed of at $211.68 per share, typically reflecting taxes due on the vesting. After these transactions, he directly owned 27,423 shares of common stock.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider LaPlume Joseph W

Role EVP, Corp Strategy & Develop

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	5,456	$0.00	$0.00
Exercise Price or Tax Liability	Common Stock	1,749	$211.68	$370K

Holdings After Transaction: Common Stock — 27,423 shares (Direct)

Footnotes (1)

1. F1. Reflects shares of common stock issued following the achievement of performance goals set forth in performance share unit awards originally granted on May 26, 2023.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider activity did CRL executive Joseph LaPlume report on January 30, 2026?

Joseph W. LaPlume reported vesting of performance-based stock and related tax share withholding. He received 5,456 CRL common shares at $0 and had 1,749 shares withheld at $211.68, ending with direct ownership of 27,423 shares.

How many Charles River Laboratories (CRL) shares does Joseph LaPlume now own?

Following the reported transactions, Joseph W. LaPlume directly owns 27,423 shares of CRL common stock. This reflects both the 5,456 performance-based shares that vested and the 1,749 shares disposed of to cover obligations on January 30, 2026.

What was the nature of the 5,456 CRL shares acquired by Joseph LaPlume?

The 5,456 CRL shares were issued at $0 upon achievement of performance goals tied to performance share unit awards. These awards were originally granted on May 26, 2023 and converted into common stock once the specified performance criteria were met.

Why were 1,749 CRL shares disposed of at $211.68 by Joseph LaPlume?

On January 30, 2026, 1,749 CRL shares were disposed of at $211.68 per share under transaction code “F”. This code typically indicates shares withheld to satisfy tax obligations arising from the vesting of equity awards, rather than an open-market sale.

What role does Joseph LaPlume hold at Charles River Laboratories (CRL)?

Joseph W. LaPlume serves as Executive Vice President, Corporate Strategy & Development at Charles River Laboratories International, Inc. His Form 4 filing reflects changes in his beneficial ownership of CRL common stock related to performance-based equity compensation.

Were the reported CRL transactions by Joseph LaPlume direct or indirect holdings?

Both transactions reported by Joseph W. LaPlume involve directly held CRL common stock. The Form 4 lists his ownership form as “D” for direct, with no indication of indirect holdings through entities such as trusts, partnerships, or family investment vehicles.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

LaPlume Joseph W

(Last) (First) (Middle)

C/O CHARLES RIVER LABORATORIES

251 BALLARDVALE STREET

(Street)

WILMINGTON MA 01887

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. [ CRL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, Corp Strategy & Develop

3. Date of Earliest Transaction (Month/Day/Year)
01/30/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/30/2026		A		5,456(1)	A	$0	29,172	D
Common Stock	01/30/2026		F		1,749	D	$211.68	27,423	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Reflects shares of common stock issued following the achievement of performance goals set forth in performance share unit awards originally granted on May 26, 2023.

	/s/ Joseph W. LaPlume	02/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.